Myovant Sciences

Nov 13, 2017

Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017

Nov 09, 2017

Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids

Oct 16, 2017

Myovant Sciences Secures Flexible Financing Commitments of up to $140 Million

Oct 02, 2017

Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids

Aug 10, 2017

Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017

Jul 19, 2017

Myovant Bolsters Executive Team with Key Management Appointments

Jun 29, 2017

Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Endometriosis-Associated Pain